Komori
Ulvac (6728) · RiskRestated

Risk of Delayed or Difficult Commercialization of New Technologies

First written in FY2016. 17 of 19 entries say "Restated". Latest entry: FY2023-Q3.

19entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2020-Q2RestatedFY2021-Q1 – FY2023-Q32016: 120162017: 220172018: 420182019: 420192020: 320202021: 220212022: 120222023: 22023
Same theme, other companies
Risk of Delayed New Product Launches Due to R&D DelaysA theme 72 companies write about · 72 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 3 of 22 companies on the "Worse" side.

44 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 72 companies compared. The sentences above are computed from all 72.
Full recordFilings, disclosures and news, newest first
  1. FY2023-Q3RestatedAnnual report

    「During the cumulative consolidated period for the third quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  2. FY2023-Q2RestatedAnnual report

    「During the cumulative consolidated period for the second quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  3. FY2022-Q3RestatedAnnual report

    「During the cumulative consolidated period for the third quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  4. FY2021-Q3RestatedAnnual report

    「During the cumulative consolidated period for the third quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  5. FY2021-Q2RestatedAnnual report

    「During the cumulative consolidated period for the second quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  6. FY2021-Q1RestatedAnnual report

    「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  7. FY2020MitigatedAnnual report

    「For development necessary for growth, we are seeking to accelerate progress by selectively concentrating our investments, while monitoring progress regularly to manage development and prevent significant delays.」

    Measures to address development-delay risk were explicitly stated, including selective concentration of investments, regular monitoring and progress management.
  8. FY2020-Q2RestatedAnnual report

    「During the cumulative consolidated period for the second quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  9. FY2020-Q1RestatedAnnual report

    「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  10. FY2019RestatedAnnual report

    「By continuing to make proactive investments in research and development, our group has continued to launch new products using cutting-edge technologies. However, if significant development delays become unavoidable and the launch of new products is delayed, this could adversely affect our group's operating results and financial position.」

    The risk that development delays could postpone the launch of new products continued to be disclosed while research and development continued.
  11. FY2019-Q3RestatedAnnual report

    「During the cumulative consolidated period for the third quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  12. FY2019-Q2RestatedAnnual report

    「During the cumulative consolidated period for the second quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  13. FY2019-Q1RestatedAnnual report

    「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  14. FY2018RestatedAnnual report

    「However, when commercialising new technologies, if events occur such as facing a phase in which development becomes significantly more difficult than planned or being forced to accept a substantial delay in development, which are unavoidable risks in commercialising new technologies, the Group's operating results and financial position could be adversely affected.」

    The risk of increased difficulty and delays in developing and commercializing new technologies continued to be disclosed.
  15. FY2018-Q3RestatedAnnual report

    「During the cumulative consolidated period for the third quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies. No quantification or occurrence of the risk was indicated.
  16. FY2018-Q2RestatedAnnual report

    「During the cumulative consolidated period for the second quarter, no new business or other risks arose. There were also no significant changes to the business and other risks described in the securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  17. FY2018-Q1RestatedAnnual report

    「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」

    It was stated that there had been no material changes in the risk of delays in, or difficulty commercializing, new technologies.
  18. FY2017RestatedAnnual report

    「However, when commercialising new technologies, if events occur such as facing a phase in which development becomes significantly more difficult than planned or being forced to accept a substantial delay in development, which are unavoidable risks in commercialising new technologies, the Group's operating results and financial position could be adversely affected.」

    While continuing R&D, the explanation of risks involving increased development difficulty and delays was maintained.
  19. FY2016First statedAnnual report

    「When commercialising new technologies, if events occur such as entering a phase in which development becomes significantly more difficult than planned or being forced to accept a substantial delay in development, which are unavoidable risks in commercialising new technologies, the Group's operating results and financial position could be adversely affected.」

    While continuing R&D investment, development delays and other factors were identified as risks.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Ulvac yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Delayed or Difficult Commercialization of New Technologies | ULVAC, Inc. (6728) | Komori